Dendreon was confident enough to say that Provenge "significantly prolongs survival".
It would appear that the result is the validation sought for many years by immunotherapy
developers that cancer vaccines not only stabilize disease but increase survival. This is very
bullish for Prima. Prima has to its advantage Orphan Drug Designation for ovarian cancer
which means it will be fast tracked through the FDA and have a 7 year patent extension in US
and 10 year patent extension in Europe.
http://www.primabiomed.com.au/projects/prodDocuments/Kinectics%20PRR%20Research.pdf
asx ann:martin rogers is catching an aeroplane, page-47
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48648 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 13814 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |